Back to Search Start Over

Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder.

Authors :
Moga L
Paradis V
Ferreira-Silva J
Gudavalli K
Indulti F
Dajti E
Nicoara-Farcau O
Tosetti G
Antonenko A
Fodor A
Vidal-González J
Turco L
Capinha F
Elkrief L
Monllor-Nunell T
Goria O
Balcar L
Lannes A
Mallet V
Poujol-Robert A
Thabut D
Houssel-Debry P
Wong YJ
Ronot M
Vilgrain V
Rampally SP
Payancé A
Castera L
Reiberger T
Ferrusquía-Acosta J
Noronha Ferreira C
Vitale G
Simon-Talero M
Procopet B
Berzigotti A
Caccia R
Turon F
Schepis F
Ravaioli F
Colecchia A
Valsan A
Macedo G
Plessier A
Rautou PE
Source :
Hepatology (Baltimore, Md.) [Hepatology] 2025 Feb 01; Vol. 81 (2), pp. 546-559. Date of Electronic Publication: 2024 Jul 02.
Publication Year :
2025

Abstract

Background and Aims: Baveno VII consensus suggests that screening endoscopy can be spared in patients with compensated cirrhosis when spleen stiffness measurement (SSM) by vibration-controlled transient elastography (VCTE) is ≤40 kPa as they have a low probability of high-risk varices (HRV). Conversely, screening endoscopy is required in all patients with porto-sinusoidal vascular disorder (PSVD). This study aimed to evaluate the performance of SSM-VCTE to rule out HRV in patients with PSVD and signs of portal hypertension.<br />Approach and Results: We retrospectively included patients with PSVD, ≥1 sign of portal hypertension, without a history of variceal bleeding, who underwent an SSM-VCTE within 2 years before or after an upper endoscopy in 21 VALDIG centers, divided into a derivation and a validation cohort. One hundred fifty-four patients were included in the derivation cohort; 43% had HRV. By multivariable logistic regression analysis, SSM-VCTE >40 kPa and serum bilirubin ≥1 mg/dL were associated with HRV. SSM-VCTE ≤40 kPa combined with bilirubin <1 mg/dL had a sensitivity of 96% to rule out HRV and could spare 38% of screening endoscopies, with 4% of HRV missed, and a 95% negative predictive value. In the validation cohort, including 155 patients, SSM combined with bilirubin could spare 21% of screening endoscopies, with 4% of HRV missed and a 94% negative predictive value.<br />Conclusions: This study gathering a total of 309 patients with PSVD showed that SSM-VCTE ≤40 kPa combined with bilirubin <1 mg/dL identifies patients with PSVD and portal hypertension with a probability of HRV <5%, in whom screening endoscopy can be spared.<br /> (Copyright © 2024 American Association for the Study of Liver Diseases.)

Details

Language :
English
ISSN :
1527-3350
Volume :
81
Issue :
2
Database :
MEDLINE
Journal :
Hepatology (Baltimore, Md.)
Publication Type :
Academic Journal
Accession number :
38954825
Full Text :
https://doi.org/10.1097/HEP.0000000000001004